Matches in Wikidata for { <http://www.wikidata.org/entity/Q89340009> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q89340009 description "artículu científicu espublizáu en payares de 2017" @default.
- Q89340009 description "im November 2017 veröffentlichter wissenschaftlicher Artikel" @default.
- Q89340009 description "scientific article published on 09 November 2017" @default.
- Q89340009 description "wetenschappelijk artikel" @default.
- Q89340009 description "наукова стаття, опублікована в листопаді 2017" @default.
- Q89340009 name "Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?" @default.
- Q89340009 name "Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?" @default.
- Q89340009 type Item @default.
- Q89340009 label "Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?" @default.
- Q89340009 label "Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?" @default.
- Q89340009 prefLabel "Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?" @default.
- Q89340009 prefLabel "Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?" @default.
- Q89340009 P1433 Q89340009-CBCF85DE-67FE-4543-9130-BB4AA4C94046 @default.
- Q89340009 P1476 Q89340009-415E4990-D610-4E85-A990-0BEA7EB96E32 @default.
- Q89340009 P2093 Q89340009-300D8FC1-7956-45A9-B9D4-E820FD2AD898 @default.
- Q89340009 P2093 Q89340009-4AE22CFA-7456-4CC7-9FB6-92CE6D7F1CF2 @default.
- Q89340009 P304 Q89340009-2843E028-0739-4E69-BF28-DA2149604F2C @default.
- Q89340009 P31 Q89340009-F4A9FFB4-6FBE-4A84-8494-714492BE11AF @default.
- Q89340009 P31 Q89340009-f9c34ba7-e5cd-4364-b6b2-a717d9f33d70 @default.
- Q89340009 P356 Q89340009-F2467F2B-7E4F-4482-9C0F-36120B2047EF @default.
- Q89340009 P433 Q89340009-BBE03C00-3210-406E-BB2E-7688AF1424A1 @default.
- Q89340009 P478 Q89340009-FB454B95-C72A-4EAB-B83E-45363B1B30F0 @default.
- Q89340009 P50 Q89340009-9E1CE402-38DE-4B63-9E29-A5ACAF2BCC05 @default.
- Q89340009 P577 Q89340009-493D4F95-4BA6-4A66-B1A1-DC2D590B41A4 @default.
- Q89340009 P698 Q89340009-78901D1C-C17D-49B6-BE16-465149CA9F5E @default.
- Q89340009 P356 CCO.2017.10.07 @default.
- Q89340009 P698 29156890 @default.
- Q89340009 P1433 Q27724839 @default.
- Q89340009 P1476 "Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?" @default.
- Q89340009 P2093 "David G Cox" @default.
- Q89340009 P2093 "Joseph Gligorov" @default.
- Q89340009 P304 "1" @default.
- Q89340009 P31 Q13442814 @default.
- Q89340009 P31 Q871232 @default.
- Q89340009 P356 "10.21037/CCO.2017.10.07" @default.
- Q89340009 P433 "1" @default.
- Q89340009 P478 "7" @default.
- Q89340009 P50 Q66829173 @default.
- Q89340009 P577 "2017-11-09T00:00:00Z" @default.
- Q89340009 P698 "29156890" @default.